ArticleJournal of general internal medicine2017
Attitudes Toward Naloxone Prescribing in Clinical Settings: A Qualitative Study of Patients Prescribed High Dose Opioids for Chronic Non-Cancer Pain.
Article in Journal of general internal medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04677387 (Addressing the Opioid Epidemic Through Community Pharmacy Engagement), which is not on this map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Addressing the Opioid Epidemic Through Community Pharmacy Engagement: Randomized Controlled Trial (Aim 2)
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 71 citations in OpenAlex.
- Experiences of people taking opioid medication for chronic non-malignant pain: a qualitative evidence synthesis using meta-ethnography.BMJ open · 2020Pooled it
- Acceptability and feasibility of naloxone prescribing in primary care settings: A systematic review.Preventive medicine · 2018Pooled it
- Naloxone Co-Dispensing with Opioids: a Cluster Randomized Pragmatic Trial.Journal of general internal medicine · 2022Trial
- Patient Insights to Improve Naloxone Access and Decision Support.The Permanente journal · 2026Article
- Variability in medication treatment of opioid use disorder in primary care: Comparison of PROUD trial intervention clinics and other exemplar clinics.Journal of substance use and addiction treatment · 2026Article
- Nudges for Naloxone in the Opioid Epidemic.Journal of general internal medicine · 2026Article
- Practical naloxone communication tips for pharmacists: Lessons learned from the Linguistic Model of Patient Participation in Care.Research in social & administrative pharmacy : RSAP · 2025Article
- Realities of opioid and gabapentinoid deprescribing in socioeconomically disadvantaged communities: a qualitative evaluation.BJGP open · 2025Article
- An evidence-based digital prescription opioid safety toolkit for national dissemination: co-design and user testing.Frontiers in digital health · 2025Article
- Clinical Decision Support to Increase Emergency Department Naloxone Coprescribing: Implementation Report.JMIR medical informatics · 2024Article
- A theoretical explanation of naloxone provision among primary care physicians and community pharmacists in Tennessee.Research in social & administrative pharmacy : RSAP · 2024Article
- Effectiveness of direct patient outreach with a narrative naloxone and overdose prevention video to patients prescribed long-term opioid therapy in the USA: the Naloxone Navigator randomised clinical trial.BMJ public health · 2024Article
- Naloxone prescription fills and use by patients treated for opioid use disorder by telehealth.Drug and alcohol dependence reports · 2024Article
- Naloxone co-prescriptions for surgery patients prescribed opioids: A retrospective cohort study.Surgery in practice and science · 2023Article
- Feasibility and Acceptability of an Overdose Prevention Intervention Delivered by Community Pharmacists for Patients Prescribed Opioids for Chronic Non-Cancer Pain.Pharmacy (Basel, Switzerland) · 2023Article
- Addressing the opioid epidemic through community pharmacy engagement: Study protocol for a randomized controlled trial.Contemporary clinical trials · 2022Article
- Intention to get naloxone among patients prescribed opioids for chronic pain.Harm reduction journal · 2022Article
- Patient perspectives on naloxone receipt in the emergency department: a qualitative exploration.Harm reduction journal · 2022Article
- A qualitative examination of naloxone access in three states: Connecticut, Kentucky, and Wisconsin.BMC public health · 2022Article
- Naloxone therapy for prescription and illicit opioid poisoning cases aged 50 + in the national poison data system, 2015-2020.Clinical toxicology (Philadelphia, Pa.) · 2022Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundOver the last 2 decades, medical providers have increasingly prescribed pharmaceutical opioids for chronic non-cancer pain, while opioid overdose death rates have quadrupled. Naloxone, an opioid antagonist, can be prescribed to patients with chronic pain to reverse an opioid overdose, yet little is known about how patients perceive this emerging practice.
objectiveThis study assessed the knowledge and attitudes toward naloxone prescribing among non-cancer patients prescribed opioids in primary care.
designQualitative study design using semi-structured interviews.
participantsAdults (N = 24) prescribed high-dose (≥100 morphine mg equivalent daily dose) chronic opioid therapy in eight primary care internal medicine, family medicine and HIV practices in three large Colorado health systems. APPROACH: Inductive and deductive methods were used to analyze interview transcripts. KEY
resultsThemes emerged related to knowledge of and benefits, barriers and facilitators to naloxone in primary care. Patients reported receiving limited education about opioid medication risks from providers and limited knowledge of naloxone. When provided with a description of naloxone, patients recognized its ability to reverse overdoses. In addition to pragmatic barriers, such as medication cost, barriers to naloxone acceptance included the perception that overdose risk stems from medication misuse and that providers might infer that they were misusing their opioid medication if they accepted a naloxone prescription, prompting an opioid taper. Facilitators to the acceptance of naloxone included medical providers' using empowering, non-judgmental communication practices, framing naloxone for use in "worst case scenarios" and providing education and training about opioids and naloxone.
conclusionsWhile patients recognized the utility of naloxone prescribing, we identified important barriers to patient acceptance of naloxone prescribing. To improve the naloxone prescribing acceptability in primary care practice, medical providers and health systems may need to enhance patient education, employ empowering, non-judgmental communication styles and adequately frame discussions about naloxone to address patients' fears.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.